Tissue Engineering of 3D bone marrow niche for hematopoietic stem cells vs acute myeloid leukemia stem cell molecular target and therapeutics discovery

造血干细胞 3D 骨髓生态位的组织工程与急性髓系白血病干细胞分子靶标和治疗发现

• 批准号: 468535
• 负责人: Sachlos Eleftherios
• 金额: $ 53.22万
• 依托单位: York University (Toronto, Ontario)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-09-01 至 2027-09-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=468535&lang=en
• 关键词: 3d Extracellular Matrix; Acute Myeloid Leukemia - Leukemic Stem Cells; Drug Discovery; Hematopoietic Stem Cells; In Vitro Myelosuppression Assay; Liquid Biopsy; Personalized Cancer Medicine; Screening; Stem Cell Niche; Tissue Engineering

Mounting scientific evidence suggests that a unique population of leukemic stem cells (LSC) are responsible for driving acute myeloid leukemia growth and resistance to drug treatment. However extracting these LSC from patients and growing them under labo

越来越多的科学证据表明，一个独特的白血病干细胞（LSC）群体负责驱动急性髓细胞白血病生长和耐药治疗。 然而，从患者体内提取这些LSC并在实验室条件下培养它们，